Overview

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Status:
Terminated
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability and efficacy of LEE011 and LGX818 when administered orally to patients with BRAF mutant melanoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Array BioPharma